D.A.B. v. Brown

570 N.W.2d 168, 1997 Minn. App. LEXIS 1219, 1997 WL 680016
CourtCourt of Appeals of Minnesota
DecidedNovember 4, 1997
DocketC2-97-817
StatusPublished
Cited by47 cases

This text of 570 N.W.2d 168 (D.A.B. v. Brown) is published on Counsel Stack Legal Research, covering Court of Appeals of Minnesota primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
D.A.B. v. Brown, 570 N.W.2d 168, 1997 Minn. App. LEXIS 1219, 1997 WL 680016 (Mich. Ct. App. 1997).

Opinion

OPINION

SHORT, Judge.

This case arises out of a physician’s prescription for Protropin, a synthetic growth hormone drug. A putative class of patients and their parents sued the physician, drug manufacturer, and drug distributor for breach of fiduciary duty, conspiracy to breach that duty, common law fraud, negligent misrepresentation, and violation of the Minnesota Prevention of Consumer Fraud Act, Minn.Stat. §§ 325F.68-.70 (1996). On appeal from a dismissal with prejudice, the putative class argues: (1) physicians should be subject to the law of fiduciaries, and (2) their complaint alleges sufficient injury to support a statutory fraud claim.

FACTS

Protropin is a drug used in the treatment of growth hormone inadequacy in children. Typically, a doctor prescribes Protropin for a child from childhood through the teenage years. The child self-administers the drug at home, several times a week. Depending on the dosage, Protropin treatment can cost between $20,000 and $30,000 per year.

Genentech, Inc. (manufacturer), developed and manufactured Protropin. In 1985, the Food and Drug Administration approved the drug and permitted the manufacturer seven years of market exclusivity. Caremark, Inc. (distributor), served as the exclusive, non-hospital based pharmacy distributor of Pro-tropin in the United States. From February of 1986 until September of 1994, Dr. David R. Brown (doctor), a Minneapolis physician specializing in pediatric endocrinology, prescribed Protropin to more than 200 patients.

On August 4, 1994, the government indicted the doctor, distributor, and others on multiple counts of mail fraud, wire fraud, money laundering, and violation of the Medie-aid/Medicare Anti-Kickback statute, 42 U.S.C. § 1320a-7b(b) (1996). On June 15, 1995, the distributor pleaded guilty to one count of mail fraud and agreed to pay several million dollars in fees, penalties, and restitution. As part of that plea agreement, the distributor stipulated that it made payments to the doctor to induce him to refer patients for Protropin-related services and supplies. A federal jury then convicted the doctor of two counts of violating the federal statute, but the trial court granted a new trial because the doctor was denied his Sixth Amendment right to trial by an impartial jury. See generally United States v. Brown, 913 F.Supp. 1324, 1333 (D.Minn.1996), aff'd, 108 F.3d 863 (8th Cir.1997).

On July 8, 1996, six patients and their parents filed suit against the doctor, distributor, and manufacturer for failing to disclose the kickback scheme. Five of the six pa *170 tients had terminated treatment with the doctor by May of 1994. On a defense motion, the trial court dismissed the lawsuit with prejudice for failure to state a claim pursuant to Minn. R. Civ. P. 9.02 and 12.02(e). The putative class appeals dismissal of the claims alleging breach of a fiduciary duty, conspiracy to breach that duty, and violation of the state fraud statute. The doctor, distributor, and manufacturer seek review of the trial court’s determination that, due to fraudulent concealment, the two-year statute of limitations commenced on August 4,1994.

ISSUES

I.Does the complaint set forth a legally sufficient claim for breach of fiduciary duty and conspiracy to breach that duty?

II.Does the complaint set forth a legally sufficient claim under the Consumer Fraud Act?

III.Do the patients’ parents have standing to sue the doctor, distributor, or manufacturer?

ANALYSIS

■ In reviewing a dismissal for failure to state a claim upon which relief can be granted, the only question before us is whether the complaint sets forth a legally sufficient claim for which relief can be granted. Elzie v. Commissioner of Pub. Safety, 298 N.W.2d 29, 32 (Minn.1980); Davis v. State Dep’t of Corrections, 500 N.W.2d 134, 135 (Minn.App.1993), review denied (Minn. July 15, 1993). We consider as true the factual allegations made in the complaint, and address solely their legal sufficiency. See Minn. R. Civ. P. 12.03 (providing for motion for judgment on pleadings).

I.

A physician is prohibited by Minn. Stat. § 147.091, subd.l (p)(l) (1996), from receiving compensation for - the referral of patients or the prescription of drugs. That statute protects consumers from economic arrangements in the medical arena that would increase the cost of health care, restrict access to goods and services, or otherwise harm consumer interests. The statute does not provide a private remedy. See Minn. R. 5620.0100 (1995) (outlining purpose of statute). Rather, a violation of the statute subjects the physician to disciplinary action by the Board of Medical Examiners. Minn. Stat. § 147.091, subd. 1 (1996). In addition, a physician who knowingly accepts remuneration in return for referrals involving Medicare or Medicaid patients is guilty of a felony under the federal anti-kickback statute, 42 U.S.C. § 1320a-7b(b) (1996).

Apart from these administrative remedies and criminal sanctions, a patient may sue a physician for failure to disclose material facts relating to treatment if the lack of disclosure prevents a patient from making an informed decision about treatment. Cor nfeldt v. Tongen, 295 N.W.2d 638, 640 (Minn.1980) (Cornfeldt II); Cornfeldt v. Tongen, 262 N.W.2d 684, 699 (Minn.1977) (Cornfeldt I). It is well accepted that patients deserve medical opinions about treatment plans and referrals unsullied by conflicting motives. See Council on Ethical and Judicial Affairs, Am. Med. Ass’n, Current Opinions of the Council on Ethical and Judicial Affairs of the American Medical Association — 1986, § 8.06, at 31 (1986) (mandating referrals be made in best interests of patient); see also David Burda, AMA Toughens Guidelines on Physician Self-Referrals, 21 Mod. Healthcare 4, 4 (1991). The putative class suggests we put “teeth” into that duty by applying traditional fiduciary concepts. See generally Marc A. Rodwin, Medicine, Money, and Morals: Physicians’ Conflicts of Interest, 234-36 (1993) (suggesting application of traditional fiduciary law to doctors engaged in kickback schemes); see, e.g., Brandt v. Medical Defense Assocs., 856 S.W.2d 667, 670 (Mo.1993) (holding physician has fiduciary duty of confidentiality, based on Hippocratic Oath, not to disclose any medical information received in connection with patient’s treatment).

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Berry v. Hennepin County
D. Minnesota, 2024
Bindner v. Traub
D. New Mexico, 2022
Fredin v. Middlecamp
D. Minnesota, 2020
Fredin v. Miller
D. Minnesota, 2020
ASI, Inc. v. Aquawood, LLC
D. Minnesota, 2020
Great West Cas. Co. v. Decker
358 F. Supp. 3d 835 (D. Maine, 2019)
Bigler-Engler v. Breg, Inc.
California Court of Appeal, 2016
Scott R. McKee, M. D. v. St. Paul Eye Clinic, P. A.
Court of Appeals of Minnesota, 2015
Pfeiffer ex rel. Pfeiffer v. Allina Health System
851 N.W.2d 626 (Court of Appeals of Minnesota, 2014)
Sipe v. STS Manufacturing, Inc.
822 N.W.2d 2 (Court of Appeals of Minnesota, 2012)
Brinkman v. Bank of America, N.A.
914 F. Supp. 2d 984 (D. Minnesota, 2012)

Cite This Page — Counsel Stack

Bluebook (online)
570 N.W.2d 168, 1997 Minn. App. LEXIS 1219, 1997 WL 680016, Counsel Stack Legal Research, https://law.counselstack.com/opinion/dab-v-brown-minnctapp-1997.